Emergent BioSolutions announced today it has named former Bausch + Lomb CEO Joseph Papa to the top job as the company, which makes the opioid overdose reversal drug Narcan, aims to return to revenue growth.

FDA

The company has filed a case with the U.S. FDA, alleging that due procedure was not followed in allowing rival Liquidia Corp’s application for a blood pressure drug.

Astellas

Kelonia Therapeutics’ in vivo gene placement system is being tapped to help Astellas Pharma expand its portfolio of in vivo CAR-T cell therapies for cancer.

Gavel

The shareholder is seeking to prevent the transaction and is alleging that Karuna’s directors had failed to disclose crucial material information regarding the company’s financial projections and sales processes, according to a case summary from Law.com. The plaintiff also claims that the defendants have conflicts of interests.

drug development, trials

Merger and acquisition activity is on the rise after the biopharma industry moved on from the COVID-19 pandemic, while the role of AI in drug development is reaching new levels.

Orr Inbar, Quant Health

2024 will be the year that AI integration will be pivotal to the continued success of those working throughout biotech and life sciences, especially for those involved in the drug discovery and regulation processes.

Wegovy

A small but rapidly growing number of U.S. adolescents began treatment with Novo Nordisk’s weight-loss drug Wegovy last year, a powerful new tool to address record rates of pediatric obesity, according to data shared exclusively with Reuters.

Pfizer has agreed to pay $93 million to settle antitrust claims by wholesale drug distributors that accused it of conspiring with India’s Ranbaxy Laboratories to delay sales of less expensive, generic versions of the cholesterol drug Lipitor.

Cancer testing biotech Freenome announced on Thursday that it has raised an additional $254 million in private financing to support the development of its multiomics-based early detection tests.

Despite launching with just days left in 2023, Sage Therapeutics’ postpartum depression therapy Zurzuvae made $1.6 million in sales, the Massachusetts-based biotech reported in Wednesday’ s fourth-quarter and full-year earnings results.